Caption Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Caption Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-62,789	Closed	-$472K	–	1524
2024 Q4	$472K	Buy	62,789 +42,789	+214%	+$325K	﹤0.01%	1122
2024 Q3	$152K	Buy	+20,000	New	+$152K	﹤0.01%	1092
2024 Q2	–	Sell	-60,000	Closed	-$331K	–	1158
2024 Q1	$305K	Buy	+60,000	New	+$337K	﹤0.01%	952
2023 Q2	–	Sell	-16,300	Closed	-$136K	–	1105
2023 Q1	$136K	Sell	16,300 -39,500	-71%	-$380K	﹤0.01%	948
2022 Q4	$641K	Sell	55,800 -94,700	-63%	-$1.18M	0.01%	865
2022 Q3	$1.9M	Buy	150,500 +30,500	+25%	+$393K	0.03%	662
2022 Q2	$1.27M	Sell	120,000 -120,000	-50%	-$1.24M	0.02%	794
2022 Q1	$3.9M	Buy	240,000 +110,500	+85%	+$1.77M	0.05%	524
2021 Q4	$1.79M	Sell	129,500 -34,100	-21%	-$451K	0.02%	824
2021 Q3	$2.35M	Sell	163,600 -341,400	-68%	-$5.38M	0.03%	700
2021 Q2	$7.98M	Buy	+505,000	New	+$6.86M	0.1%	249
2019 Q3	–	Sell	-4,400	Closed	-$16K	–	707
2019 Q2	$16K	Sell	4,400 -20,600	-82%	-$124K	﹤0.01%	635
2019 Q1	$203K	Buy	+25,000	New	+$214K	0.01%	506

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caption Management's BCRX Position: Q1 2025 in Review

Caption Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2025, closing a stake of 62,789 shares — an estimated $472K sold.

Caption Management first reported a position in BCRX in Q1 2019 and held it in 13 quarters. The position peaked at $7.98M in Q2 2021. 274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.

Caption Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Caption Management sold 62,789 BioCryst Pharmaceuticals shares in Q1 2025, an estimated $472K.
Caption Management first reported a position in BioCryst Pharmaceuticals in Q1 2019 and held it in 13 quarters.
Caption Management's BioCryst Pharmaceuticals position peaked at $7.98M in Q2 2021.
274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.